The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ICML 2023 | Everolimus and itacitinib in patients with HL R/R to brentuximab vedotin and checkpoint inhibitors
Jakub Svoboda, MD, University of Pennsylvania, Philadelphia, PA, shares some insights into a study evaluating the combination of everolimus, an mTOR inhibitor, and itacitinib, an oral JAK inhibitor, in patients with Hodgkin lymphoma (HL) who have failed or are intolerant to brentuximab vedotin (BV) and checkpoint inhibitors. Dr Svoboda first discusses the rationale behind combining these agents, and then summarizes the promising results observed so far. This interview took place at the 17th International Conference on Malignant Lymphoma (ICML), held in Lugano, Switzerland.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
